Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-06-08
1999-12-14
Kight, John
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
544247, 544343, 546 64, 546 85, 546 86, 546 87, 514 92, 514249, 514250, A01N 4342, A01N 4358, C07D23900, C07D47100
Patent
active
06001847&
DESCRIPTION:
BRIEF SUMMARY
This invention relates to a series of tetracyclic derivatives, to processes for their preparation, pharmaceutical compositions containing them, and their use as therapeutic agents. In particular, the invention relates to tetracyclic derivatives which are potent and selective inhibitors of cyclic guanosine 3', 5'-monophosphate specific phosphodiesterase (cGMP specific PDE) having utility in a variety of therapeutic areas where such inhibition is thought to be beneficial, including the treatment of cardiovascular disorders.
Thus, according to a first aspect, the present invention provides compounds of formula (I) ##STR2## and salts and solvates (e.g. hydrates) thereof, in which: R.sup.0 represents hydrogen, halogen or C.sub.1-6 alkyl; selected from phenyl, halogen, --CO.sub.2 R.sup.a and --NR.sup.a R.sup.b ; selected from oxygen, nitrogen and sulphur, and being optionally substituted by one or more C.sub.1-6 alkyl, and optionally linked to the nitrogen atom to which R.sup.1 is attached via C.sub.1-6 alkyl; --OR.sup.a, --NR.sup.a R.sup.b, halogen, hydroxy, trifluoromethyl, cyano and nitro; selected from oxygen, nitrogen and sulphur; and ##STR3## (i) a bicyclic ring attached to the rest of the molecule via one of the benzene ring carbon atoms and A is a 5- or 6-membered heterocyclic ring as defined in point (h); and
The term "C.sub.1-6 alkyl" as used herein denotes any straight or branched alkyl chain containing 1 to 6 carbon atoms, and includes methyl, ethyl, n-propyl, iso-propyl, n-butyl, pentyl, hexyl and the like.
The term "halogen" as used herein denotes fluorine, chlorine, bromine and iodine.
A particular group of compounds according to formula (I) are those wherein R.sup.0 represents any of hydrogen, methyl, bromine and fluorine, although of course the definition of R.sup.0 given in formula (I) includes within its scope other C.sub.1-6 alkyl and halogen groups.
Aptly, R.sup.1 may represent a substituent selected from methyl, ethyl optionally substituted by one or more chlorine atoms, butyl, cyclohexyl and benzyl.
Other suitable R.sup.1 substituents include hydrogen; cycloalkyl groups, such as cyclopropyl; C.sub.1-6 alkyl, typically ethyl or propyl, substituted by an --NR.sup.a R.sup.b substituent, such as a dimethylamino substituent; phenyl optionally linked to the nitrogen atom to which R.sup.1 is attached via a C.sub.1-6 alkyl chain, such as ethyl or the like; and C.sub.1-6 alkyl, e.g. methyl, substituted by --CO.sub.2 R.sup.a, such as --CH.sub.2 CO.sub.2 Et or the like.
Suitable heterocyclic rings within the definition of R.sup.1 include pyridyl, morpholinyl, piperazinyl, pyrrolidinyl and piperidinyl. Generally such heterocyclic rings are linked to the nitrogen atom to which R.sup.1 is attached via a C.sub.1-6 alkyl chain, more appropriately a C.sub.1-4 alkyl chain.
A particularly apt substituent represented by R.sup.2 is ##STR4##
Other suitable R.sup.2 substituents include thienyl, pyridyl, furyl and phenyl, wherein phenyl can be substituted by one or more substituents selected from --OR.sup.a (e.g. methoxy), --NR.sup.a R.sup.b (e.g. dimethylamino), halogen (in particular chlorine or fluorine), hydroxy, trifluoromethyl, cyano and nitro.
Alternatively, R.sup.2 may represent a suitable C.sub.3-6 cycloalkyl group, such as cyclohexyl or the like.
The pharmaceutically acceptable salts of the compounds of formula (I) which contain a basic centre are acid addition salts formed with pharmaceutically acceptable acids. Examples include the hydrochloride, hydrobromide, sulphate or bisulphate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate, gluconate, methanesulphonate, benzenesulphonate and p-toluenesulphonate salts. Compounds of the formula (I) can also provide pharmaceutically acceptable metal salts, in particular alkali metal salts, with bases. Examples include the sodium and potassium salts.
It is to be understood that the present invention covers all appropriate combinations of particular and preferred groupings hereinabove.
Particular individu
REFERENCES:
patent: 3644384 (1972-02-01), Schulenberg
patent: 3717638 (1973-02-01), Schulenberg
patent: 3917599 (1975-11-01), Saxena et al.
patent: 4188390 (1980-02-01), Campbell
patent: 4686228 (1987-08-01), Campbell et al.
patent: 5145852 (1992-09-01), Virag
patent: 5270323 (1993-12-01), Milne, Jr. et al.
A. Bowman et al., Br. J. Pharmac., (1984), 81, 665-674.
F. Trigo-Rocha et al., Am. J. Physiol., (1993, Feb.), 264, H419-H422.
J. Reiser et al., Br. J. Dis. Chest, (1986), 80, 157-163.
P. Bush et al., J. Urol., (1992, Jun.), 147, 1650-1655.
F. Holmquist et al., J. Urol. (1993, Oct.), 150, 1310-1315.
R. Rudd et al., Br. J. Dis. Chest, (1983), 77, 78-86.
E. McMahon et al., J. Pharmacol. Exp. Thera., (1989), 251, 1000-1005.
F. Holmquist et al., Acta Physiol. Scand., (1991), 143, 299-304.
G. Barbanti, Urol. Res., (1988), 16, 299-302.
L. Ignarro et al., Biochem. and Biophys. Res. Comm., (1990), 170(2), 843-850.
J. Krall et al., Bio. Reprod., (1988), 39, 913-922.
M. Wilkins et al., Proc. Natl. Acad. Sci., USA, (1990, Aug.), 87, 6465-6469.
M. Wilkins et al., J. Clin. Invest., (1990, Apr.), 85, 1274-1279.
J. Rajfer, N. Eng. J. Med., (1992, Jan.), 326(2), 90-94.
H. Knispel, Urol. Res., (1992), 20, 253-257.
G. Gwinup, Annals. of Internal Medicine, (1988, Jul.), 162-163.
A. Zorgniotti, J. Urol., (1992, Apr.), 147(4), 308A.
K. Azadzoi et al., J. Urol., (1992, Nov.), 148, 1587-1591.
K. Azadzoi et al., J. Urol., (1992, Jan.), 147, 220-225.
C. Sparwasser et al., J. Urol., (1994, Dec.), 152, 2159-2163.
T. Lue, "Campbell's Urology," 6th Ed., Chap. 16, P. Walsh et al., Eds., W.B. Saunders Co., 709-728 (1991).
N. Kim et al., J. Clin. Invest., (1991), 88, 112-118.
S. Francis et al., in J. Beavo et al. eds. "Cyclic Nucleotide PDEs," Ch. 5 (1990) 117-140.
R. Weishaar et al., J. Med. Chem., (1985), 28:5, 537-542.
H. Ahn et al., Biochem. Pharmacol., (1989), 39:19, 3331-3339.
C. Lugnier et al., Biochem. Pharamcol., (1986), 35:10, 1743-1751.
J. Doremieux et al., Ann. Urol. Paris, (1987), 21(6), 429-434.
D. Green et al., Geriatrics, (1993, Jan.), 48(1), 46-58.
M. Webster et al., Hematol. Oncol. Cl. of N. Am., (1990, Feb.), 4(1), 265-289.
F. Holmquist et al., Acta. Physiol. Scand., (1991), 141, 441-442.
J. Taher et al., J. Urol., (1993, Apr.), 149, 285A.
S. Uckert et al., , 495A.
W. Aronson et al., J. Urol., (1991), 145 (4 Supp.), 341A.
P. Bush et al., Fed. Am. Soc. Exp. Biol., (1991), 5(4), 175.
P. Bush et al., Fed. Am. Soc. Exp. Biol., (1992), 6(4), 2092.
W. Aronson et al., J. Urol., (1992), 147 (4 Supp.), 454A.
P. Bush et al., Circulation, (1993, May), 87 Supp. V, V-30-V-32.
R. Pickard et al., J. Urol., (1993, May) 149 (4 Supp.), 245A.
R. Pickard et al., Clin. Pharamcol., (1993, Jan.), 35(5), 536P-537P.
F. Trigo-Rocha et al., J. Urol., (1993, Apr.), 149, 872-877.
M. Krupp et al., J. Cardiovas. Pharmacol., (1989), 13 (Supp. 2), S11-S19.
"Physicians' Desk Reference," (1992), 683,1099-1100, 1344, 1941-1943.
R. Morales et al., World J. Urol., (1990), 8, 80-83.
J. Cortijo, Br. J. Pharmacol., (1993, Feb.), 108(2), 562-568.
E. Kim et al., J. Urol., (1995), 153, 361-365.
S. Korenman et al., JAGS, (1993, Apr.), 41(4), 363-366.
K. Allenby et al., Angiology, (1991), 42, 418-420.
H. Hamilton et al., J. Med. Chem., (1987), 30, 91-96.
H. Padma-Nathan et al., Sem. in Urol., (1986, Nov.), vol. IV, No.4, 236-238.
J. Beavo et al., TiPS, (1990, Apr.), 11, 150-155.
S. Korenman et al., Clin. Res., (1988), 36, 123A.
D. Halsted et al., J. Urol., (1986, Jul.), 136, 109-110.
W. Thompson, Pharmac. Ther., (1991), 51, 13-33.
M. Geimbycz et al., Clin. and Exper. Allergy, (1992), 22, 337-344.
C. Nicholson et al., TIPS, (1991, Jan.), 12, 19-27.
J. LeBlanc et al., Eur. J. Cardiothorac Surg., (1993), 7, 211-215.
C. Stief et al., J. Urol., (1992, Nov.), 148, 1437-1440.
C. Stief et al., World J. Urol., (1991), 9, 237-239.
C. Clyne et al., Br. J. Surg., (1987, Apr.), 74, 246-248.
V. Mirone et al., Acta. Urol. Ltd., (1992), Suppl. 4, 11-12.
P. Bush, Ph.D. Thesis (1992), pp. 159-160.
T. Lincoln, Pharmac. Ther., (198
Daugan Alain Claude-Marie
LaBaudiniere Richard Frederic
Desai Rita
ICOS Corporation
Kight John
LandOfFree
Chemical compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemical compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemical compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-863725